WO2021234301A1

WO2021234301A1 - Use of a protein extract of moringa oleifera seeds as an anti-pollen agent

Info

Publication number: WO2021234301A1
Application number: PCT/FR2021/050899
Authority: WO
Inventors: Christine Jeanmaire
Original assignee: Basf Beauty Care Solutions France Sas
Priority date: 2020-05-20
Filing date: 2021-05-20
Publication date: 2021-11-25
Also published as: CN115697367A; FR3110402A1; JP2023527160A; FR3110402B1

Abstract

The present invention relates to the use of a protein extract of non-germinated, de-fatted Moringa oleifera seeds as an anti-pollen agent. It also relates to the protein extract of non-germinated, de-fatted Moringa oleifera seeds for use in treating and/or preventing and/or reducing the onset of a pollen allergy and/or conditions and/or symptoms associated with a pollen allergy.

Description

USE OF A PROTEIN EXTRACT FROM MORINGA OLEIFERA SEEDS AS AN ANTI-POLLEN AGENT

The present invention relates to the field of household hygiene products, in particular cosmetology and dermatology. The present invention relates to the use of a protein extract of non-germinated seed of Moringa as a protective agent against pollens as well as a pharmaceutical product, in particular dermatological product for preventing and / or reducing allergies to pollen and its manifestations. pathological.

The genus Moringa includes some 14 plant species (including Moringa peregrina, M. aptera, M. concanensis, M. drouhardii, M. hildebrandtii, M. iongituba), of which Moringa pterygosperma (synonym Moringa oieifera) is the best known.

This is a fast growing tree that adapts very well to varying conditions, thriving throughout the tropics, Asia, Africa and South America. The fruits, 30 to 50 cm long, hang like drumsticks, hence the English name "drumstick tree", and its green pods are appreciated as a vegetable all over the world. As a result, the seeds are seldom allowed to ripen for oil production.

The different parts of the tree (leaves, roots, root bark, flowers, seeds) are used in traditional medicine in the countries where it grows.

Moringa seeds are characterized by the presence of an oil whose content varies between 21 and 53% depending on the species and the maturity of the seeds. For the Moringa oieifera species, the levels mentioned in the literature range from 21 to 34%. Due to its excellent oxidation stability and its good perfume fixing properties, Moringa oil, also called Behen or Ben oil, was in ancient civilizations, the oil most used by formulators. ointments for cosmetic and religious purposes. This oil has been used by formulators in cosmetics until the last century and its use has been "rediscovered" recently.

Apart from their oil content, Moringa seeds have more recently gained the attention of researchers for their protein extract. Thus, application EP1064008 describes the use of a protein extract from Moringa seeds on the skin and the mucous membranes for their softening, physiological conditioner, moisturizing, restructuring, repairing, anti-wrinkle effect and as an antipollution active.

Such an extract is in particular marketed by BASF under the name Purisoft® for its purifying and anti-pollution effect on pollution microparticles and Puricare® for its effect of protecting the hair against pollution.

Application WO02 / 096448, for its part, describes the use of a protein extract from a seed that may or may not be delipidated in the fields of deodorization, removal of bad odors, cleanliness, personal hygiene, oral hygiene, dental care.

More recently, patent application FR 3,076,460 also describes the use of a protein extract from Moringa seeds to prevent and / or reduce and / or eliminate the unsightly and / or uncomfortable effects of the skin and / or mucous membranes including the flora. beneficial commensal is impaired, in particular to prevent and / or reduce and / or delay the secretion of sebum and its unsightly and / or unpleasant and / or uncomfortable manifestations, in particular to prevent and / or reduce and / or delay the formation of stitches black and / or comedogenesis and / or shiny appearance of the skin, and / or maintain and / or improve homogeneity of the complexion of the skin and / or mucous membranes, for example by removing and / or reducing redness and / or irregularities, and / or preventing and / or treating the sensation of heating and / or heat of the skin and / or mucous membranes and / or to prevent and / or reduce hair loss and / or body hair, and / or to prevent and / or reduce dandruff. However, none of these documents describes or suggests that the Moringa seed protein extract can be useful for protecting surfaces against pollens, and more specifically the skin, mucous membranes and / or integuments.

The present invention therefore relates to a new use of a protein extract of deoiled non-germinated seed of Moringa o / eifera which has never been described or suggested in the prior art.

In fact, the inventors have discovered that such an extract made it possible to prevent the adhesion of the pollen grains on the skin, the mucous membranes and / or integuments and more generally on any type of surface (example 2). This extract therefore has a very interesting anti-pollen effect and is therefore a product of choice in the treatment of surfaces, in particular skin and / or mucous membranes and / or hair exposed to pollen, in particular in sensitive and / or allergic people. to pollens.

Pollen is a very fine dust made up of microscopic organic grains produced and released by the anthers of plants. The pollen grains, more or less ovoid in shape, can measure from 5 to 200 microns, and whose average size varies between 20 and 60 microns.

A pollen grain is a very complex whole which is distinguished by a very particular organic structure. Its rigid outer layer, which has a protective role, is called the exine. The exine has a different aspect according to the species which makes it possible to characterize a plant species only by the observation of its pollen grains. The exine is lined protuberances, crevices which are filled in by a predominantly lipidic substance, called the pollen mantle. The latter is sticky and gives the pollen its particular adhesive properties. This adhesion is thus ensured by the ornamentations of the exine and / or the viscous lipid coating which covers it, thus allowing its attachment to the pollinating animals.

Pollen is, however, responsible for global health problems. In Asia, it is especially cedar pollen that is described as a real seasonal plague. In 2019, an increase in cedar pollen allergy was reported. Sensitization to cedar pollen is detected in 78% of Japanese people, and 41% of them complain about the pollen. The same problem has also been described in North America with mountain cedar. In Europe, ragweed pollens, which are very allergenic, could quadruple by 2050. In France, the mugwort-leaved ragweed (Ambrosia artemisiifolia), native to North America, has already colonized Burgundy, l 'Auvergne and the Rhône-Alpes region and its pollen can cause allergies which are manifested in particular by pathologies such as rhinitis, sinusitis, conjunctivitis, tracheitis or even cause asthma attacks. These problems also affect the skin dramatically, as the pollen induces allergic skin inflammation which is characterized by dryness, redness and rashes. In addition, exposure to pollen exacerbates eczema. Pollen-induced damage is potentiated by urban pollutants. Studies show that atmospheric pollutants, in particular pollution microparticles, can increase the amount of allergen present in pollen grains as well as their ability to be released into the air, free allergenic sites and thus increase their allergenicity. . (D'amato G et al, 2007: allergie pollen and pollen Allergy in Europe; Laaidi M, 2011: pollen allergies, pollution and climate: Literature review; Sedghy F et al, 2018: Interaction between Air poiiutants and pollen Grains: the roie on the rising trend in aiiergy).

Treatments for pollen allergy often require the use of antihistamines and / or corticosteroids which have many side effects. Protection against pollens responsible for allergies remains the preferred avenue to avoid resorting to allergy treatments. The difficulty, however, lies in the fact that the impact of pollen on health is not only linked to outdoor exposure in a pollinated area, but also exists inside homes. In fact, the grains adhere to all surfaces such as fabrics, in particular clothes, shoes, but also the skin, mucous membranes and integuments and in particular to the hair fiber. Thus, the pollen grains will adhere to these surfaces and then be released inside homes. This phenomenon is particularly important with long hair.

Consequently, there is a significant need in the field of domestic hygiene, more specifically in cosmetics and dermatology, to provide ingredients making it possible to limit and / or decrease the quantity of pollens present on surfaces in general, more specifically the skin, the mucous membranes, and / or the integuments, in particular the hair, in particular by preventing their adhesion, and which are easily available.

The present invention therefore relates to the use of a protein extract of deoiled non-germinated seed of Moringa oieifera, advantageously of a protein extract of delipidated non-germinated seed, in particular of a protein extract of deoiled meal, more particularly delipidated, of non-germinated seeds, more preferably non-germinated seed almonds, of Moringa oieifera, as an anti-pollen agent. For the purposes of the present invention, the term “anti-pollen agent” means any compound or mixture of compounds having the property of limiting and / or reducing the quantity of pollens present on surfaces, in particular external ones, more specifically the skin, mucous membranes and / or integuments, in particular the hair, in particular by preventing their adhesion, and / or to prevent their dissemination.

The property of limiting and / or reducing the quantity of pollens present on surfaces, in particular external ones, in particular the hair, can be measured by the test presented in Example 2.

In particular, the use according to the invention is for the treatment of surfaces of the skin and / or mucous membranes and / or integuments such as the hair, exposed to pollens, and preferably in persons sensitive and / or allergic to pollens. It is in particular a cosmetic use.

Within the meaning of the present invention, “cosmetic” is understood to mean a non-pharmaceutical, non-therapeutic use which is not intended for the prevention and / or treatment of skin and / or mucous membranes and / or integuments qualified as pathological by a specialist. in the field, such as a dermatologist. It is therefore for use on healthy skin and / or mucous membranes and / or integuments.

The term “healthy skin and / or mucosa and / or healthy integument” is understood to mean all or part of an area of skin including the scalp and / or mucous membrane and / or healthy skin, in particular human, therefore not exhibiting infection. , scar, disease or skin condition such as candidiasis, impetigo, psoriasis, eczema, acne, ichthyosis, gingivitis or dermatitis or wounds or injuries or canker sores or ulceration or burns and / or other dermatoses, or aphtosis or inflammation or irritation, or hives or allergy such as contact allergy. For the purposes of the present invention, “skin” is understood to mean the skin of all or part of the body, in particular the human body, including the scalp, chosen from the face, hands, arms, neckline, legs, neck, etc. back, shoulders, stomach, wrists, forearms, ankles, thighs, neck. In particular, the skin is that which may be in contact with pollen, that is to say which is not covered by clothing. It is therefore more particularly the face, hands, neck and décolleté.

For the purposes of the present invention, the term “mucosa (s)” means the ocular, nasal mucosa and / or the oral mucosa, in particular the labial buccal mucosa, preferably the labial, ocular and / or nasal mucous membranes.

The term “integuments” means the nails and “keratin fibers”.

The term “keratin fibers” means the hair fiber (the hair), the eyelashes, the eyebrows, the hairs in particular of the nasal mucosa, of the ears, of the beard and / or of the mustache.

Preferably, the application is topically, advantageously on specific parts and / or areas of the body exposed to pollens, in particular chosen from the face, hands, arms, neckline, labial, nasal and / or mucous membranes. ophthalmic, the body hair, the eyelashes, the eyebrows and / or the hair, preferably the hair.

The protein extract of deoiled non-germinated seed of Moringa oleifera according to the invention is topically acceptable. For the purposes of the present invention, the term “topically acceptable” is understood to mean an ingredient suitable for topical application, non-toxic, non-irritating to the skin and / or the mucous membranes and / or the integuments, which does not induce pain. allergic response and is not chemically unstable. For the purposes of the present invention, the term “pollen” means the pollen grains of plants, preferably those having an average equatorial diameter (called E) ranging from 20 to 60 microns and / or an average polar axis (called P) ranging from 20 to 60 microns.

Preferably, the pollens are chosen from the most allergenic pollens, in particular, plant pollens chosen from those:

- of the Betulaceae family in particular the Betura genera, in particular the birch, Aulnus in particular the Alder, Corylus in particular the hazel tree,

- from the Cupressaceae family, in particular the Cypress (Cupressus) and the Japanese Cedar (Cryptomeria japonica), the Mountain Cedar (Mulange Cypress),

- from the Pinaceae family, in particular Cedars,

- of the Asteraceae family, in particular Ambrosia (Ambrosia artemisiifolia),

- from the Poaceae (or grasses) family,

- oak (Quercus) and / or plane trees (Platanus).

Preferably, the pollens are those of birch, hazel, Japanese cedar, mountain cedar, grasses and / or ambrosia.

According to the invention, the use of the protein extract of non-germinated seed of Moringa oleifera according to the invention is not for improving the barrier function of the skin nor for increasing the hydration of the skin and / or mucous membranes neither for the treatment of dry skin, nor to soothe the skin and / or mucous membranes, in particular the skin and / or dry mucous membranes, nor to soften and / or reduce the feeling of fatigue of the skin and / or mucous membranes . In particular, the use of the protein extract of deoiled non-germinated seed of Moringa oleifera according to the invention is not either for protecting the skin and / or the mucous membranes against pollution, more particularly urban pollution (such as heavy metals, exhaust gases and / or cigarette smoke), damage caused by pollution, and / or to purify the skin and / or mucous membranes by removing pollution particles that make the skin and / or impure mucous membranes such as carbon particles.

Furthermore, the use according to the invention is not either to prevent and / or reduce and / or eliminate the unsightly and / or uncomfortable effects of the skin and / or mucous membranes of which the beneficial commensal flora is altered, to prevent and / or reduce and / or delay sebum secretion and its unsightly and / or unpleasant and / or uncomfortable manifestations, to prevent and / or reduce and / or delay the formation of blackheads and / or comedogenesis and / or appearance shiny skin, and / or maintain and / or improve the uniformity of the complexion of the skin and / or mucous membranes, for example by removing and / or reducing redness and / or irregularities, and / or preventing and / or treating the sensation of heating and / or heat of the skin and / or mucous membranes and / or to prevent and / or reduce hair loss and / or body hair, and / or to prevent and / or reduce dandruff.

In another alternative embodiment, the protein extract of deoiled ungerminated seed of Moringa oleifera is applied to an inert surface exposed to pollen, including household surfaces, fibers, including fabrics, such as clothing and / or clothing. laundry.

For the purposes of the present invention, the term “topical route” is understood to mean the application of the protein extract of non-germinated deoiled seed of Moringa oleifera and / or of the composition and / or of the ingredient according to the invention to the skin. surface of the skin and / or mucous membranes, in particular the external surface, in particular by direct application or by spraying.

For the purposes of the present invention, the term “cosmetic and / or pharmaceutical ingredient (s)” is understood to mean one or more plant extracts and / or one or more natural or synthetic molecules and / or their mixtures intended for cosmetic and / or pharmaceutical application. Cosmetic ingredients are defined in particular by the international nomenclature of cosmetic ingredients (INCI).

For the purposes of the present invention, the term “suitable cosmetic or pharmaceutical vehicle” means that the composition or components thereof are suitable for use in contact with the skin and / or human mucous membranes without toxicity, incompatibility, undue instability, allergic response, or their equivalents.

The extract according to the invention can be obtained by various extraction methods known to those skilled in the art, advantageously chosen from maceration, with or without stirring, hot decoction, grinding including grinding with ultrasound or with water. using a blender. Preferably, the extraction is carried out by maceration, advantageously still with stirring.

The extraction can be carried out at a temperature of 4 ° C to 300 ° C, preferably 20 ° C to 80 ° C, it being understood that 20 ° C corresponds to ambient temperature, advantageously between 20 and 25 ° C.

The extraction will be carried out for a period of 30 minutes to 12 hours, preferably for a period of 1 hour to 5 hours, more preferably for a period of 1 hour to 2 hours. Very advantageously, the extraction will be carried out for a period of 1 hour.

The extract according to the invention can be obtained by extraction in a practical polar solvent, advantageously chosen from the group consisting of water, an alcohol, a glycol, a polyol, a water / alcohol mixture, from 99/1 to 1 / 99 (w / w), a water / glycol mixture of 99/1 to 1/99 (w / w) and a water / polyol mixture of 99/1 to 1/99 (w / w) (such as water mixed with ethanol, glycerol and / or butylene glycol and / or other glycols such as xylitol and / or propanediol, etc.), advantageously in water as the sole solvent. In particular, the extract is obtained by aqueous extraction.

For the purposes of the present invention, the term “extract obtained by aqueous extraction” means any extract obtained by extraction with an aqueous solution containing more than 60% by weight, advantageously at least 70% by weight, in particular at least 80% by weight. , more particularly at least 90% by weight, in particular at least 95% by weight, of water relative to the total weight of the aqueous solution, even more advantageously not containing glycol and in particular not containing glycol. alcohol, more particularly containing only water. The extract can be obtained from an amount of 0.1% to 20% of fresh or dry material, preferably dry, advantageously from 1% to 10%, still advantageously from 5% to 10%, very advantageously from in an amount of 10% by weight of dry matter, of the non-germinated delipidated seeds of the Moringa oleifera plant, relative to the total weight of the non-germinated delipidated seeds of the plant and of the solvent.

In an advantageous embodiment, the protein extract of deoiled non-germinated seed of Moringa oleifera is as described in patent EP1064008 and is marketed by BASF under the trade name Purisoft®.

It is in particular a water-soluble extract, more particularly obtained by extraction in a practical polar solvent, advantageously in water.

The extraction process is advantageously that described in patent EP1064008 and in particular comprises the following steps: a) - extraction of the oil from the seeds of Moringa oleifera, advantageously using a press or by extraction at reflux in an apolar solvent such as hexane; b) - extraction of the cake or deoiled flour obtained in step a) with a practical polar solvent, in particular chosen from alcohols, polyols, glycols, water and their mixture in any proportion, advantageously with a aqueous solvent, ie water-based, even more advantageously with water as the sole solvent, so as to obtain a crude extract, advantageously as described in Example 1a.

Advantageously, the extraction is carried out at room temperature.

The aqueous solvent can be a saline solution at different pHs or a buffered medium, more preferably at a pH between 4 and 8.

The method can also comprise an additional step c) after step b) of precipitation of the crude extract without modifying the pH of the aqueous crude extract obtained in step b) so as to obtain a basic pH, in particular greater than 8, more preferably greater than 11, for example using NaOH, and recovery of the precipitate obtained, advantageously as described in example lb.

The precipitate can then be washed and then dissolved in water so as to remove the insolubles and to obtain an extract in the form of a protein concentrate.

The method may also comprise, after step c) of precipitation, an additional step d) of decantation so as to allow better precipitation of the proteins, for example as described in Example 1c. In particular, this step is carried out at a temperature below ambient temperature, advantageously at 4 ° C., more advantageously for at least 6 hours, in particular overnight.

Instead of steps c) and d), a step e) can be implemented after step b) comprising bringing the crude aqueous extract obtained in step b) into contact with carboxymethylcellulose, advantageously for lhOO, in particular at room temperature, so as to load it with the protein extract. This step can be followed by a step f) of bringing the charged carboxymethylcellulose obtained in step e) into contact with an aqueous saline solution, advantageously a NaCl solution, having a pH greater than 7, advantageously 7.5, then recovery of the eluate thus obtained which corresponds to a partially purified extract.

The protein extract of deoiled non-germinated seed of Moringa oleifera is advantageously an extract of shelled seeds, that is to say advantageously an extract of the kernel of the seeds only (without its envelope or shell).

The method can therefore comprise a step prior to step a) of husking the seeds.

Finally, the extracts obtained (crude extract, protein concentrate and / or partially or totally purified extract) can be centrifuged and / or filtered and / or distilled, so as to recover the water-soluble fraction and be in liquid form. Preferably, the supernatant obtained after centrifugation is filtered, advantageously at a cut-off threshold of 0.45 μm. Additional decolorization and / or deodorization steps can be carried out on the extracts at any stage of the extraction and according to techniques known to those skilled in the art. In particular, the extracts can be decolorized with activated charcoal. According to a particular embodiment, the extract according to the invention is obtained by extraction of ungerminated seed cakes, in particular deoiled, more advantageously delipidated, in an aqueous saline solution at a pH of about 5 followed by elimination of the proteins. of high molecular weight. The supernatant is recovered and constitutes an extract according to the invention. The extracts can also be concentrated by evaporation of the solvent or dried, for example by lyophilization or by atomization. The extracts will then be in powder form.

In a particular embodiment of the invention, in particular for its use in dermatology, the Moringa oleifera extract obtained will be sterilized.

In a particularly advantageous embodiment, the protein extract of deoiled non-germinated seed of Moringa oleifera contains, on the basis of the dry extract, a protein content, in particular of native proteins, of between 0.01 and 100% in weight, advantageously at least 25% by weight, in particular at least 40% by weight, more particularly at least 45% by weight.

The proteins of the protein extract according to the invention advantageously have a molecular weight of between 6,500 and 13,000 Da, advantageously between 7,100 and 11,000 Da, measured by chromatography.

In particular the protein extract of deoiled ungerminated seed of Moringa oleifera does not contain alkaloid (such as for example spirochin), Pterygospermin, isothiocyanates (such as for example 4-2-L-Rhamnosyloxy benzyl isothiocyanate) or kaempferol.

The extract according to the invention can be formulated in any form suitable for its application to the surface exposed to pollen, in particular the external surface.

In one embodiment of the invention, the extract will be incorporated into a hygiene and / or maintenance composition, in particular detergent, further comprising at least one suitable excipient. This composition may comprise other agents of interest such as conventional disinfectants, detergents, surfactants and bactericides.

In another embodiment, the extract according to the invention can be used in the form of a cosmetic or pharmaceutical ingredient. intended to be incorporated into a cosmetic or pharmaceutical composition, and further comprising a suitable cosmetic or pharmaceutical vehicle.

In this case, the extract according to the invention is in another embodiment preferably dissolved in and / or diluted in a solvent, in particular polar solvent, such as water, advantageously further comprising glycerin as in the product marketed under the name Purisoft® or Puricare® and in particular as described in Example 3a).

The extract according to the invention in another embodiment can be atomized on an atomization support such as maltodextrin for example and be in the form of a powder in particular as described in example 3b).

Advantageously, when the ingredient is in liquid form such as that described in Example 3a), the extract according to the invention is present in the ingredient in a content of between 0.01 and 10% by weight of material. dry relative to the total weight of the ingredient, advantageously between 1 and 5% by weight.

Advantageously, when the ingredient is in solid form, in particular powder as described in Example 3b), the extract according to the invention is present in the ingredient in a content of between 10 and 60%, by weight of dry matter relative to the total weight of the ingredient, advantageously between 30 and 50% by weight.

The extract according to the invention optionally in the form of a cosmetic or dermatological ingredient can also be in the form of a cosmetic or pharmaceutical composition, intended for topical administration, preferably on the skin, further comprising a cosmetic vehicle or pharmaceutical appropriate. The cosmetic or pharmaceutical ingredient, in particular dermatological in liquid form and in particular that of example 3a), can be used in a cosmetic or pharmaceutical composition, in particular dermatological, preferably at a content by weight of dry matter relative to the weight. total of the composition of between 0.01 and 10%, advantageously between 0.1 and 5%, in particular between 1 and 3%. The cosmetic or pharmaceutical ingredient, in particular dermatological ingredient in solid form and in particular that of Example 3b), can be used in a cosmetic or pharmaceutical composition, in particular dermatological, preferably at a content by weight of dry matter relative to the weight. total of the composition of between 0.001 and 5%, advantageously between 0.01 and 1%.

In one embodiment of the invention, the extract will be included in the cosmetic or pharmaceutical composition in a content of between 0.0001% and 20% by weight of dry matter relative to the total weight of the composition, preferably between 0.001 % and 10% by weight, advantageously between 0.01 and 5% by weight.

The compositions according to the invention can contain any suitable solvent and / or any suitable vehicle and / or any suitable excipient, optionally in combination with other compounds of interest. They may in particular contain a cosmetically or dermatologically acceptable excipient chosen from surfactants, preservatives, buffering agents, swelling agents, chelating agents, biocidal agents, denaturants, opacifying agents, pH adjusters, reducing agents. , stabilizers, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, bactericides, odor absorbers, mattifying agents, conditioning agents, texturing agents, shine agents , pigments, dyes, fragrances and chemical or mineral sun filters, trace elements, essential oils, sweeteners, taste modifiers. These combinations are also covered by the present invention. The CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic and pharmaceutical ingredients commonly used in the cosmetic and pharmaceutical industry, which are in particular suitable for oral administration and / or topical use.

Advantageously, the excipient (s) are chosen from the group comprising polyglycerols, esters, polymers and cellulose derivatives, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, stabilizers based on sucrose, vitamin E and its derivatives, xanthan gums, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, silicones, protein hydrolysates, betaines, aminoxides, plant extracts, sucrose esters , titanium dioxides, glycines, and parabens, and more preferably from the group consisting of steareth-2, steareth-21, 15-glycol stearyl ether, cetearyl alcohol, phenoxyethanol, methylparaben, l 'ethylparaben, propylparaben, butylparaben, butylene glycol, caprylyl glycol, natural tocopherols, glycerin, dihydroxyketyl sodium phosphate, isopropyl hydroxyketyl ether, g lycol stearate, triisononanoine, octyl cocoate, polyacrylamide, isoparaffin, laureth-7, a carbomer, propylene glycol, hexylene glycol, glycerol, bisabolol, a dimethicone, sodium hydroxide, PEG 30-dipolyhydroxystérate, capric / caprylic triglycerides, cetearyl octanoate, dibutyl adipate, grape seed oil, jojoba oil, magnesium sulfate, EDTA, cyclomethicone, xanthan gum , citric acid, sodium lauryl sulfate, mineral waxes and oils, isostearyl isostearate, propylene glycol dipelargonate, propylene glycol isostearate, PEG 8, beeswax, hydrogenated palm heart oil glycerides, lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, titanium dioxide, lactose, sucrose, low density polyethylene, isotonic saline solution, and mixtures thereof.

The cosmetic or pharmaceutical composition or the extract according to the invention, optionally in the form of a cosmetic or pharmaceutical ingredient, can be provided in all the galenical forms conventionally used for topical application such as liquid or solid forms or even in the form of liquid under pressure. They can in particular be formulated in the form of an aqueous or oily solution, a cream or an aqueous gel or an oily gel, in particular in a jar or in a tube, in particular a shower gel, a shampoo, a milk, an emulsion, an oily gel. hydrogel, a microemulsion or a nanoemulsion, in particular oil-in-water or water-in-oil or multiple or silicone, a serum, a lotion, in particular in a glass or plastic bottle or in a measuring bottle or in an aerosol, an ampoule, a liquid soap, a paste, a dermatological bar, an ointment, a foam, an aerosol, a mask, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of a stick, in particular in stick or in powders , especially makeup. In particular, the composition is in the form of a serum, a lotion, a cream, a milk, an ointment, a paste, a mousse, an emulsion, or 'a hydrogel, a shower gel, a mask, a stick of a patch, or makeup powders, advantageously a cream or a lotion.

In the case of administration by the musosal route, the cosmetic or pharmaceutical composition or the extract according to the invention optionally in the form of a cosmetic or pharmaceutical ingredient, may be in the form of an eye drops, a lotion, an aerosol, a gel, or a mucoadhesive composition.

The cosmetic or pharmaceutical composition may further comprise other active ingredients for the treatment of the skin and / or mucous membranes and / or integuments inducing a complementary or synergistic effect with the extract according to the invention, chosen for example from among

a combination of sodium hyaluronate, pullulan and sodium alginate, in particular marketed in a formulation containing serine, trehalose, urea and glycerin under the name PatcH20 ™ by the applicant;

- cosmetic agents intended for the care of sensitive skin such as a plant extract of Cestrum latifolium as described in application WO2009 / 112590 for example marketed under the name Symbiocell ™ by the applicant, a butter extracted from the fruit of the tree Irvingia gabonensis marketed under the name Irwinol ™ by the applicant, an extract of the root of Eperua falcata marketed under the name Eperuline ™, an N-acetyl-L-Tyrosyl-L-Prolyl-L-Phenylalanyl-L-Phenylalaninamide ( INCI: acetyl tetrapeptide 15) sold under the name Skinasensyl ™ by the applicant.

The cosmetic composition may also contain one or more other ingredients that are active on the cutaneous and / or mucosal microbial flora and / or active on the barrier function of the skin, in particular moisturizing and / or soothing active ingredients, among which an oligosaccharide obtained by enzymatic synthesis marketed. by the company Solabia under the name of BioEcolia ™ or an alpha-glucooligosaccharide complex marketed by the same company under the name of Ecoskin ™, an extract of Alisma plantago-aquatica, an extract of Argania spinosa / Lipofructyl ™ Argan ^ a mixture of ceramides (Sphingoceryl ™ VEG), purifying extracts of Boldo (Betapur ™), products based on inulin or fructooligosaccharides, extracts of bifidobacteria or an extract of Orthosiphon stamineus to combat oily skin (MAT-XS ™ Bright), a natural extract of honey marketed by the applicant under the name Melhydran ™ for its moisturizing property, an extract of flax marketed under the name Oligolin ™ by the Applicant, a yeast extract modified by biotechnology and marketed by the Applicant under the name Relipidium ™, a root extract of Pueraria lobata marketed under the name Inhipase ™ by the Applicant, a derivative of beta-glucan obtained from baker's yeast marketed by Mibelle under the name CM-Glucan Forte ™ and / or an extract of Mirabilis jalapa marketed under the name Pacifeel ™ by Sederma.

Advantageously, a subject of the invention is also a method of treating surfaces to limit and / or reduce the quantity of pollens present on the surfaces, more specifically the skin, the mucous membranes, and / or the integuments, preferably the hair, in particular by preventing their adhesion and / or to prevent the dissemination of pollens, said surfaces being exposed to pollen grains, said method comprising the steps:

- The identification of a surface likely to be in contact with a pollen, in particular on the individual of an area of skin and / or mucous membrane and / or integument likely to be in contact with a pollen, the aforesaid skin and / or mucous membranes and / or integuments being healthy skin and / or mucous membranes and / or integuments, and

- the topical application to this surface, in particular to this area of skin and / or mucous membrane and / or integument, of a composition, in particular cosmetic, containing the protein extract of deoiled non-germinated seed of Moringa oleifera according to 'invention in an amount effective to limit and / or reduce the amount of pollens present on surfaces, in particular the area of skin and / or mucous membrane and / or integument, said skins and / or mucous membranes and / or integuments being healthy skin and / or mucous membranes and / or integuments.

The present invention also relates to a protein extract of deoiled non-germinated seed of Moringa oleifera, advantageously a protein extract of delipidated non-germinated seed, in particular a protein extract of deoiled cake, more particularly delipid, of non-germinated seeds, more advantageously of almonds. of non-germinated seeds, of Moringa oleifera, for its use, in particular topically, in the treatment and / or prevention and / or reduction of the occurrence of pollen allergy and / or pathologies and / or symptoms associated with pollen allergy, especially "hay fever", rhinitis, sinusitis, conjunctivitis, tracheitis, watery eyes, sneezing attacks, itching, headache, pruritus, anosmia, rhinorrhea, nasal obstruction and / or asthma attacks.

The present invention is particularly intended for the care and / or pharmaceutical treatment, in particular dermatological care of the skin, mucous membranes and / or integuments, in particular hair, of people allergic to pollen, that is to say in whom exposure to grains pollen triggers a type I hypersensitivity reaction.

For the purposes of the present invention, the term “pollen allergy” means type I hypersensitivity triggered by pollen antigens.

Other objects, characteristics and advantages of the invention will become clear to those skilled in the art upon reading the explanatory description which refers to examples and to the figures which are given only by way of illustration and which can in no way limit the scope of the invention.

The examples form an integral part of the present invention and any feature which appears new with respect to any state of the prior art from the description taken as a whole, including the examples, forms an integral part of the invention in its function and in its generality.

Thus, each example has a general scope.

On the other hand, in the examples, and unless otherwise indicated, the temperature is expressed in degrees Celsius and the pressure is atmospheric pressure.

Brief description of the drawings

Figure 1 is a photograph of a control lock of hair treated with water not comprising the extract according to the invention for about 16:00 on which was sprinkled a determined amount of Japanese cedar pollen, seen under the microscope according to the protocol of example 2.

Figure 2 is a photograph of a lock of hair treated with water comprising 0.1% (w / w) of the extract according to example 1d and formulated according to example 3a) for about 16:00 on which was sprinkled with a determined quantity of Japanese cedar pollen, seen under a microscope according to the protocol of Example 2.

Figure 3 is a photograph of a lock of hair treated with water comprising 1% (w / w) of the extract according to example 1d and formulated according to example 3a) for about 16:00 on which was sprinkled with a determined quantity of Japanese cedar pollen, seen under a microscope according to the protocol of Example 2.

EXAMPLES

Example 1: preparation of the Moringa extract according to the invention

The Moringa extract is prepared according to the process described in patent EP1064008, in particular as described below:

EXAMPLE Preparation of extract 1a)

Moringa o / eifera almonds obtained after husking the seeds and containing 33.4% (weight / weight) of oil are delipidated by two successive extractions at reflux in hexane and, after filtration, the flour is dried in an oven at 40 ° C and has a residual oil content of 2.5%.

In a reactor, 200 g of delipidated flour are added to 2 liters of distilled water. After 10 minutes of stirring, the pH is adjusted to 7.5 by adding 4N NaOH and the extraction is then carried out for one hour at room temperature while maintaining the pH at 7.5. The insoluble matter is removed by centrifugation for 15 min. at 5000 g.

The supernatant is collected and then filtered through 0.45 μm: thus obtaining 1.77 liters of yellow filtrate, containing 4.69% of dry extract and exhibiting a protein concentration measured by the Biuret technique of 21.54. g / l (ie a protein purity on the basis of the dry extract of 45.92%). The extract is dehydrated by atomization and 65.72 grams of atomizate are obtained, having an estimated protein content of 54.7% (N x 6.25).

If we take into account the peaks eluted between the excluded volume and the total volume of the column, the chromatographic profile resulting from the gel permeation analysis on a Superose 12HR column of this extract shows a major fraction which represents 52% of the surface area and which corresponds to molecular weights between 7,800 and 11,000 Da. The presence of shoulders in this peak confirms the existence of several compounds and the molecular weight range is close to that found in the literature for monomers (6500 and 7000 Da) and dimers (13000 Da) of proteins. Moringa flocculants.

EXAMPLE lb (Preparation of extract lb)

300 g of delipidated flour are extracted according to Example 1a so as to obtain a crude aqueous extract. The pH of the filtrate (2.74 liters) is adjusted to 11.8 by gradual addition of 4N NaOH. Precipitation begins at around pH 8.0 (clear cloudiness of the solution) and after 30 minutes the solution is centrifuged for 15 min at 5000 g. The sticky precipitate is collected (43.2 g wet) then washed twice with 500 ml of distilled water at pH 11.8.

The precipitate is then dissolved in 270 ml of distilled water (i.e. 10% of the initial volume) and the pH of the solution is continuously adjusted to 4.5 with 6N HCl so as to allow solubilization of the precipitate (dispersion is facilitated by the use of an apparatus of the type known under the designation Turax).

After 30 min of stirring, the mixture is centrifuged for 15 min. at 5000 g to remove the insoluble and the supernatant is filtered through a Büchner filter fitted with a Whatman No. 41 filter. 260 ml of clear, yellow protein concentrate are thus obtained, which is dehydrated by lyophilization.

In this way, 11.5 grams of lyophilisate are obtained with a protein content of 90-95% by weight.

The gel permeation analysis on a Superose 12HR column of this extract shows a major fraction which represents 70% of the surface area and which corresponds to molecular weights of approximately 8800 Da.

EXAMPLE le (Preparation of extract le)

The almond oil obtained by shelling the seeds of Moringa oleifera is extracted by pressure on a press of the type known under the name KOMET and the cake obtained is crushed in order to obtain a homogeneous flour.

A crude extract is prepared from 1.24 kg of cake according to the procedure described in Examples la and lb.

The proteins are precipitated at pH 11.8 according to example lb, but an additional step of settling overnight at + 4 ° C. is introduced in order to allow better precipitation of the proteins.

The precipitate is treated under the same conditions as in Example 1b (the pH of the solution for reconstituting the precipitate, however, being 6 instead of 4.5). The protein concentrate thus obtained (1.05 liter at 4.59% of dry extract) is dehydrated by atomization and 34.6 g of atomizate are collected, i.e. an atomization yield based on the dry extract of 71.5%.

The protein content based on the nitrogen assay (N x 6.25) is over 90% (about 95%).

EXAMPLE ld (Preparation of extract ld ")

A crude extract is prepared from 150 g of cake according to the procedure described in Examples la, lb and le.

After filtration through 0.45 μm, 1.35 liters of clear yellow filtrate are obtained. 100 grams of Carboxymethylcellulose (CM52, WHATMAN) are equilibrated for 30 minutes in 500 ml of distilled water at pH 7.5.

The mixture is filtered through a Büchner funnel fitted with a WHATMAN No. 42 filter, then the cellulose is collected and again equilibrated in 500 ml of water at pH 7.5.

After removal of the aqueous medium by filtration, the cellulose is brought into contact, with stirring for one hour at room temperature, with the aqueous extract of Moringa oleifera almond cake.

The non-adsorbed compounds (fractions whose chromatographic profile is shown in broken lines in FIG. 3) are removed by filtration on a Büchner funnel and the “loaded” cellulose is then washed twice with one liter of distilled water at pH 7.5. then filtered through Büchner.

The cellulose is then brought into contact with 120 ml of a 60 g / l NaCl solution, pH 7.5, for 30 minutes.

The proteins eluted in NaCl medium are recovered by filtration on Büchner (the chromatographic profile of the proteins adsorbed on CM 52 and eluted in NaCl 60 g / l medium is shown in solid lines in FIG. 3). 110 ml of filtrate are thus obtained with a dry extract content of 9.63% and with a protein concentration of 64.6 g / l (ie a protein purity on the basis of the dry extract of 67%).

The gel permeation analysis on a Superose 12HR column of this extract shows a major fraction which represents 70% of the surface and which corresponds to molecular weights of approximately 7,100 Da.

The solution can be desalted by dialysis, or by ultrafiltration and dehydrated by lyophilization, atomization or any other suitable means. According to example 1d, the extract was atomized on a maltodextrin support and formulated according to example 4b) in order to be tested in the following examples.

Example 2 Evaluation of the effect of the anti-pollen agent according to the invention on the adhesion of pollen grains to the hair.

Protocol: Preliminary tests have been carried out and have shown that the pollen grains of the Japanese cedar tree (Cryptomeria japonica) strongly adhere to the strands of hair on which they are sprinkled in a closed test chamber. Strands of normal long female hair) previously treated with the ingredient obtained according to example 1d and formulated according to example 3a) for about 16 hours, and used at doses of 0.1% and 1% (w / w ) in water by weight relative to the total weight of the water / ingredient mixture. The locks of hair are then brushed and a defined quantity of Japanese cedar pollen is sprinkled on these locks and the whole is stirred in a closed test chamber for 5 to 10 minutes. Observation of the locks of hair under a microscope made it possible to visualize and quantify by counting by image analysis the proportion of pollen grains having adhered to the hair. A control comprising water alone without the ingredient was carried out in the same way. Results: Figures 1, 2 and 3 illustrate the results obtained. This test demonstrates that the prior application of the anti-pollen agent according to the invention significantly and dose-dependent reduced the adhesion of the pollen grains to the locks of hair. At 1% by weight in water, the ingredient of example 3a) reduced by 70% the amount of pollen grains having adhered to the locks of hair.

The same test was repeated on fabric fibers instead of strands of hair and also showed the property of the product to significantly reduce pollen uptake. Example 3: Cosmetic or pharmaceutical ingredients according to the invention containing the Moringa extract according to the invention

Example

A cosmetic or pharmaceutical liquid ingredient having the following formulation in percent by weight is prepared. Table 1

Example 3b ")

A solid ingredient in powder form having the following formation is prepared: Table 2

Example 4: Composition according to the invention in the form of a lotion for the body and / or the face:

Table 3

The lotion is prepared by the usual methods in the field well known to those skilled in the art, by mixing the 6 phases.

Example 5: Composition according to the invention in the form of a milk for the body and / or the face

A cosmetic product in the form of a milk for the body and / or the face may, for example, have a composition by weight, constituted from the following aqueous and fatty phases, as indicated below. Table 4

The process for preparing face and / or body milk essentially consists in bringing the fatty phase to 80 ° C, in bringing the water of the aqueous phase also to 80 ° C and in dissolving the preservative therein (Elestab 4112), then pouring the aqueous phase into the fatty phase with turbine stirring and gradually cooling with stirring, then adding thereto, at around 50 ° C, the aqueous stock solution of Moringa protein extract, then the perfume and, finally, to continue the stirring until completely cooled.

Example 6: Composition according to the invention in the form of a face cream

A cosmetic product in the form of a cream for the body and / or the face may, for example, have a composition by weight, constituted from the following aqueous and fatty phases, as indicated below. Table 5

The process for preparing the cream for the face consists essentially in bringing the fatty phase to 80 ° C, in bringing the aqueous phase also to 80 ° C and in dissolving Elestab 4112 therein, in separately preparing the stock solution of extract Moringa Oleifera protein, pouring the fatty phase into the aqueous phase with turbine stirring, then, at around 50 ° C., introducing the stock solution of Moringa extract therein and finally continuing stirring until cooling.

Claims

1. Use of a protein extract of deoiled non-germinated seed of Moringa oleifera, advantageously of a protein extract of delipidated non-germinated seed, in particular of a protein extract of deoiled cake, more particularly delipid, of non-germinated seeds, more advantageously almonds from non-germinated seeds, from Moringa oleifera, as an anti-pollen agent.

2. Use according to claim 1, for limiting and / or reducing the quantity of pollens present on surfaces, more specifically the skin, mucous membranes, and / or integuments, in particular the hair, in particular by preventing their adhesion and / or to prevent their spread.

3. Cosmetic use according to any one of claims 1 or 2, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is applied to a surface exposed to pollens, in particular domestic surfaces, clothing, skin. , the mucous membranes and / or the integuments and preferably the hair.

4. Use according to any one of claims 1 to 3, characterized in that the pollens are the pollens of plants chosen from those of the Betulaceae family in particular the Betura genera, in particular birch, Alnus in particular Alder, Corylus. especially hazelnut; of the Cupressaceae family, in particular the Cypress (Cupressus) and the Japanese Cedar (Cryptomeria japonica), the Mountain Cedar (Mulange Cypress); of the Pinaceae family, in particular the Cedars; of the Asteraceae family, in particular Ambrosia (Ambrosia artemisiifolia), of the Poaceae (or grasses) family, those of oak (Quercus) and / or those of plane trees (Platanus), again preferably those of birch, hazel, Japanese Cedar, Mountain Cedar, grasses and / or Ambrosia.

5. Use according to any one of claims 1 to 4, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is applied topically to specific parts and / or areas of the body exposed to pollen chosen from among the face, the hands, the arms, the décolleté, the labial, nasal and / or ophthalmic mucous membranes, the hairs, the eyelashes, the eyebrows and / or the hair, preferably the hair.

6. Use according to any one of claims 1 to 5, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is a water-soluble extract, in particular obtained by extraction in a polar solvent, advantageously in water. .

7. Use according to any one of claims 1 to 6, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera contains, based on the dry extract, a protein content, in particular native proteins. , between 0.01 and 100% by weight, advantageously at least 25% by weight.

8. Use according to any one of claims 1 to 7, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is an extract of shelled seeds.

9. Use according to any one of claims 1 to 8, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is in the form of a cosmetic ingredient intended to be incorporated into a cosmetic composition, and further comprising a suitable cosmetic vehicle.

10. Use according to claim 9, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is present in the cosmetic ingredient in liquid form in a content of between 0.01 and 10% by weight of dry matter. relative to the total weight of the ingredient, advantageously between 1 and 5% by weight or in the form solid in a content of between 10 and 60% by total weight of the ingredient, advantageously between 30 and 50% by weight.

11. Use according to any one of claims 1 to 10, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera or the cosmetic ingredient comprising it is in the form of a cosmetic composition intended for a topical administration further comprising a suitable cosmetic vehicle.

12. Use according to claim 11, characterized in that the protein extract of non-germinated deoiled seed of Moringa oleifera is present in the cosmetic composition in a content of between 0.0001% and 20% by weight of dry matter relative to the total weight. of the composition, advantageously between 0.01 and 5% by weight.

13. Use according to any one of claims 11 or 12 characterized in that the composition is in the form of a serum, a lotion, a cream, a milk, an ointment, or '' a paste, a mousse, an emulsion, a hydrogel, a shower gel, an aerosol, a mask, a stick, a patch, or makeup powders , advantageously of a cream or a lotion.

14. Protein extract of deoiled non-germinated seed of Moringa oleifera, for its use, in particular topically, in the treatment and / or prevention and / or reduction of the occurrence of pollen allergy and / or pathologies and / or symptoms associated with pollen allergy, in particular "hay fever", rhinitis, sinusitis, conjunctivitis, tracheitis, watery eyes, sneezing attacks, itching, headache, pruritus, anosmia, rhinorrhea, obstruction nasal and / or asthma attacks.

15. Protein extract of deoiled non-germinated seed of Moringa oleifera for its use according to claim 14, characterized in that that the protein extract of deoiled non-germinated seed of Moringa oleifera is as defined in any one of claims 1 to 8.

16. Protein extract of deoiled non-germinated seed of Moringa oleifera, for its use according to any one of claims 14 or 15, characterized in that the protein extract of deoiled non-germinated seed of Moringa oleifera is in the form of ' a pharmaceutical ingredient or a pharmaceutical composition further comprising a suitable pharmaceutical carrier.